CVS Health Corp Earnings - Q1 2026 Analysis & Highlights
CVS Health reported strong Q1 2026 results with significant margin recovery at Aetna, raised full-year guidance, and emphasized technology investments and regulatory adaptation as key strategic priorities amid evolving healthcare industry dynamics.
Key Financial Results
Revenue of over $100 billion in Q1 2026, representing an increase of over 6% year-over-year, driven by growth across all operating segments.
Adjusted operating income of approximately $5.2 billion, increasing over 12% from the prior-year quarter, primarily driven by improvement in the Health Care Benefits segment.
Adjusted earnings per share (EPS) of $2.57, a meaningful increase of over 14% from the prior-year quarter.
Cash flow from operations of approximately $4.2 billion generated during the quarter.
Leverage ratio improved to 3.84 times at the end of the first quarter.
Business Segment Results
Health Care Benefits generated nearly $36 billion of revenue in the quarter, an increase of over 3% from the prior-year, primarily driven by government business growth partially offset by exit from individual exchange business.
Health Care Benefits ended the quarter with approximately 26 million medical members, declining sequentially by approximately 600,000 members due to individual exchange business exit, partially offset by commercial fee-based membership growth.
Health Care Benefits adjusted operating income of approximately $3 billion with a medical benefit ratio (MBR) of 84.6%, reflecting substantial improvement from the prior-year quarter.
Health Services segment generated revenues of over $48 billion, an increase of 11% year-over-year, driven by pharmacy drug mix and brand inflation partially offset by pharmacy client price improvements.
Health Services adjusted operating income of approximately $1.5 billion, a decrease of approximately 7% from the prior-year quarter, primarily driven by continued pharmacy client price improvements.
Pharmacy & Consumer Wellness segment delivered revenues of nearly $32 billion, remaining relatively consistent with the prior-year quarter, with same-store total revenues increasing approximately 3%.
Pharmacy & Consumer Wellness same-store pharmacy sales grew over 3% compared to the prior-year quarter, driven by pharmacy drug mix, increased prescription volumes, and brand inflation, with same-store prescription volumes increasing nearly 7%.
Pharmacy & Consumer Wellness retail pharmacy script share of over 29% represents meaningful growth compared to the same quarter last year.
Pharmacy & Consumer Wellness adjusted operating income decreased approximately 9% from the prior year to approximately $1.2 billion, though strong underlying business performance exceeded expectations.
Health Care Delivery revenues grew over 15% compared to the same quarter last year, primarily driven by Oak Street Health.
Capital Allocation
Quarterly dividend of nearly $850 million returned to shareholders during the first quarter.
Cash at parent and unrestricted subsidiaries of approximately $2.2 billion at the end of the first quarter.
Share repurchase program remains suspended as management focuses on strengthening the balance sheet and reducing leverage, with evaluation of capital deployment opportunities to occur later in 2026.
Industry Trends and Dynamics
Medicare Advantage rates for 2027 represented a step in the right direction towards greater sustainability but remain insufficient to offset underlying medical cost trends.
Medical cost trends remain above historical levels and have pressured the entire industry for the past several years.
GLP-1 medications represent a significant cost challenge for clients, with only about half of clients covering GLP-1s for weight loss indication, creating ongoing affordability challenges.
Specialty pharmacy now represents half of pharmacy benefit revenues, requiring focused cost management through biosimilars and generics.
Prior authorization standardization efforts across the industry represent over 50% of PA volume by year-end, with Aetna already at 88% of procedures standardized.
Competitive Landscape
Aetna has the fewest medical services subject to prior authorization in the industry and approves more than 95% of eligible prior authorizations within 24 hours, with over 80% approved in real time.
Biosimilar conversion success demonstrated through Humira conversion of over 90% of eligible patients, with similar conversion rates expected for Stelara biosimilar transition beginning July 1, 2026.
Retail pharmacy script share growth of 200 basis points in GLP-1 category driven by ability to serve both insured and direct-to-consumer markets.
TrueCost transparent pricing model launched over two years ago positions CVS ahead of industry transition toward net cost economics and greater transparency.
Macroeconomic Environment
Medical cost trends remain elevated and above historical levels, creating ongoing pressure across the healthcare industry.
Inflation in pharmacy drug mix and brand inflation continue to drive revenue growth across segments.
Regulatory environment at federal and state levels is driving industry transition toward greater transparency, lower out-of-pocket costs, and net cost pricing models.
Growth Opportunities and Strategies
Health100 platform launch planned for later in 2026 as an AI-native, state-of-the-art technology and service platform allowing seamless connection for any payer, PBM, pharmacy, or provider.
Health100 app designed as the consumer's front door to a fully integrated healthcare experience regardless of pharmacy banner or benefit card brand.
Insulin affordability commitment ensures every American has access to certain insulin products for $25 per month across the network of more than 60,000 pharmacies, including 9,000 CVS pharmacies.
Stelara biosimilar transition on July 1, 2026 to exclude branded Stelara from commercial template formularies, with expectation that majority of customers will pay $0 out-of-pocket for this therapy.
AI deployment across CVS Health for years to improve operations and drive efficiencies, with focus on improving consumer experiences, engagement, and outcomes.
Technology investments in Aetna focused on three buckets: AI and broader technology investment, cost structure improvement and efficiency, and improving work processes to enable colleagues to focus on higher-value activities.
Oak Street Health performance improvement through disciplined growth, V28 adoption, optimized payer partnerships, and clinical-led model optimization.
Commercial business growth across all parts of the business including fully insured with disciplined pricing, supported by innovative product suite and leading technology.
Provider-payer partnerships expansion with 18 million members in commercial book to reduce friction and create seamless member experience.
Financial Guidance and Outlook
Full-year 2026 adjusted EPS guidance increased to a range of $7.30 to $7.50, up from previous range of $7.00 to $7.20, representing an increase of $0.30 or more than 4%.
Full-year total revenues expected to be at least $405 billion.
Full-year cash flow from operations updated to at least $9.5 billion, reflecting improved underlying performance primarily related to working capital.
Health Care Benefits full-year adjusted operating income expected in a range of approximately $4.0 billion to $4.34 billion, an increase of $420 million relative to prior guidance.
Full-year MBR expected within previous guidance range of 90.5% plus-or-minus 50 basis points.
Pharmacy & Consumer Wellness full-year adjusted operating income expected to be at least $6.18 billion, an increase of approximately $90 million from prior guidance.
Full-year enterprise adjusted operating income expected in the range of $15.53 billion to $15.87 billion.
Earnings split expected to be roughly 60-40 between first-half and second-half of 2026.
Medicare Advantage target margins of approximately 3% expected to be achieved by 2028, with meaningful progress expected in 2027.
Mid-teens EPS CAGR through 2028 remains the company's growth target, with multiple pathways to achieve this growth despite Tennessee regulatory outcome.
Regulatory and Policy Environment
FTC settlement negotiations ongoing with focus on simpler pricing, greater transparency, and lower out-of-pocket costs for patients at the pharmacy counter.
Comprehensive Addiction and Recovery Act (CAA) and federal legislation driving industry transition from rebate guarantees to drug-level specific rebates and pricing guarantees.
Tennessee legislation disappointing to management, expected to raise costs for the state and threaten pharmacy access, with implementation not taking effect until middle of 2028.
Point-of-sale rebates in Aetna fully insured business over the last eight years demonstrate commitment to passing transparency to consumers.
Prior authorization standardization commitment through AHIP to standardize services for most common prior authorizations representing over 50% of PA volume by year-end.
Medicare Advantage Business
Medicare Advantage business showed strong year-over-year improvement with disciplined strategy into 2026 planning and strong execution during Annual Enrollment Period (AEP).
Medicare Advantage membership landed in line with expectations with improved geographic mix and product mix.
Leading star scores carried into 2027 to support continued momentum and progress toward target margins.
Medicare Advantage rates for 2027 appreciated for partnership progress from advanced notice to final notice, though shortfall relative to trend remains.
